RBC Capital Reiterates Sector Perform on Biomarin Pharmaceutical, Maintains $100 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated a Sector Perform rating on Biomarin Pharmaceutical (NASDAQ:BMRN) and maintained a $100 price target.
August 06, 2024 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital analyst Luca Issi has reiterated a Sector Perform rating on Biomarin Pharmaceutical and maintained a $100 price target.
The reiteration of a Sector Perform rating and maintenance of the $100 price target suggests that RBC Capital sees no significant change in the company's outlook. This is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100